Congenital central hypothyroidism occurs either in isolation
npg l e t t e r s serum free thyroxine (FT4) concentration was 79% (13%) of the lower limit of the reference range for age and assays. Except for two infants with lower values, all ranged between 67-94% of the reference range. Serum TSH concentrations were within the reference range in all cases (range of 0.8-6.0 mU/l, mean 2.6 mU/l). The FT4/TSH ratio was therefore lower than in controls (3.94 versus 5.73; Mann-Whitney test P = 0.002). Mean (s.d.) serum triiodothyronine (T3) concentration in nine 1-to 3-week-old IGSF1-deficient infants was 98% (12%) of the lower limit of the reference range for age (range of 83-121%) 1 . In seven older cases, T3 concentration was in the lower half of the reference range. Within families, we observed considerable differences in the extent of hypothyroidism. In eight infants (2.5-5 weeks old) and eight older subjects (0.4-65.5 years old), standard TRH tests were conducted (Supplementary Table 2 ). In the infants, the peak TSH concentration was 4.5-16.0 mU/l. A similar range was observed in previous reports on congenital central hypothyroidism 2, 3 , and concentrations are lower than observed in agematched controls (14-37 mU/l) 3 . At later ages (7.3-63 years), peak TSH concentrations were between 4.3 and 8.5 mU/l, which is in the lower half of the reported reference ranges for males (3.7-12.5 mU/l (ref. 4) or 4.1-13.9 mU/l (ref. 5)). In eight subjects, the increment of serum FT4 (mean (s.d.) = 14.2% (7.9%)) was lower than that reported for controls (mean (s.e.m.) = 23.9% (2.7%)), but the FT3 response to TRH was normal (36.3% versus 41.8% in controls) 6, 7 (Supplementary  Table 3 ). We could demonstrate central hypothyroidism in 5 of 20 female heterozygous carriers (data not shown).
Serum prolactin concentrations were decreased in 18 of 26 cases ( Table 1) . Cases A-III.7, H-III.3, I-III.2 and K-II.3 showed growth retardation in childhood, associated with biochemical GH insufficiency, and were treated with biosynthetic GH. In young adulthood, GH stimulation tests were normal in the three subjects who had discontinued treatment. Clinical and biochemical details are presented in the Supplementary Note. In three cases, magnetic resonance imaging (MRI), performed because of macrocephaly (A-III.11), central hypothyroidism (C-III.1) and GH deficiency (K-II.3), was abnormal, showing a frontoparietal hygroma, hypoplasia of the corpus callosum and small stalk lesion, respectively. In eight other cases, MRIs were normal.
Testicular development showed a characteristic pattern involving normal testicular volume in childhood, increase in testicular volume from approximately 11 years of age onward, while serum testosterone was still low, relatively large testes for serum testosterone (>2 years advance), in adolescence and adult macroorchidism (>30 ml by Prader orchidometer, >18.3 ml by ultrasound) 8 (Table 1) . No abnormalities were observed in testicular morphology by ultrasound. In 10 out of 11 evaluable cases, testosterone production was delayed, defined as a late increase in serum testosterone concentration (<0.8 nM = <23 ng/dl at 13.0 years) 9 and/or a pubertal growth spurt that was >2 years delayed (compared to Dutch reference data 10 ).
The most recent (July 2012) clinical data on height, body mass index (BMI) and pituitary-gonadal hormones for cases are shown in Table 2 . Mean height was close to the average for population references, but BMI was higher than 25 in 11 out of 13 adults and higher than +2 s.d. score (SDS) in 5 out of 13 children. Plasma testosterone concentration was normal in most cases. A-I.4, who underwent surgery for npg l e t t e r s testicular torsion and in whom the remaining testis was atrophic, had low testosterone concentration and elevated gonadotropins before the start of testosterone substitution, and, currently, at the age of 86.7 years, his inhibin B and anti-Müllerian hormone (AMH) concentrations are very low. The two subjects with severe obesity (D-I.3 and F-II.8) had low plasma testosterone concentrations, but, because of low plasma sex hormone-binding globulin (SHBG) concentration, the free androgen index was normal. Plasma luteinizing hormone (LH), follicle stimulating hormone (FSH), inhibin B and AMH concentrations were within reference ranges in the majority of cases, but plasma FSH concentration was always higher than LH concentration and was above the reference range in six cases. The response to gonadotropinreleasing hormone (GnRH) (100 µg administered intravenously) was higher for LH than for FSH concentration in all except two subjects. Inhibin B concentration tended to be high (elevated in four subjects), and AMH concentration was relatively low (decreased in five subjects) relative to the reference range. Serum high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, triglyceride, glucose, insulin and C-peptide concentrations did not indicate the presence of a metabolic syndrome (data not shown).
The identified IGSF1 mutations are summarized in Figure 1c . Families C and D harbored the same single-nucleotide deletion (c.2248delG (p.Glu750Lysfs*28)). In families E and F, we observed submicroscopic gene deletions of different sizes that affected IGSF1 and no other annotated gene. Affected members of families G-I and K had missense or nonsense mutations, and there was a singlenucleotide duplication (c.3596dupT (p.Glu1200Argfs*3)) in family J. All variants were confirmed by Sanger sequencing (Supplementary Table 4 ), map to conserved regions of the gene, are not present in available databases (dbSNP, 1000 Genomes Project, the Leiden Open Variance Database (LOVD), the Human Gene Mutation Database (HGMD) and Genome of the Netherlands (GoNL, pilot data of 500 unrelated individuals)) and were not previously reported.
IGSF1 encodes a plasma membrane immunoglobulin superfamily glycoprotein 11, 12 . The canonical IGSF1 protein has 12 C2-type immunoglobulin loops, a transmembrane domain and a short intracellular C tail (Fig. 1c) . A hydrophobic linker separating immunoglobulin loops 5 and 6 targets the protein for obligate cotranslational proteolysis, such that only the C-terminal domain (CTD) traffics to the plasma membrane 13 . Human IGSF1 and mouse Igsf1 mRNAs are abundantly expressed in Rathke's pouch (the developing pituitary primordium; Fig. 2a ) and in adult pituitary gland and testis [13] [14] [15] [16] [17] (Supplementary Fig. 2 ). IGSF1 protein is detected in mouse thyrotropes, somatotropes and lactotropes but not in gonadotropes (Fig. 2b) 
l e t t e r s
The phenotypes of cases with intragenic mutations are highly similar to those of individuals with complete IGSF1 deletion (families E and F) ( Table 1) , suggesting loss of IGSF1 function in all cases. The identified mutations in families A-D and G-K map to the IGSF1 CTD coding region (Fig. 1c) . We therefore examined expression and posttranslational regulation of IGSF1 mutants in heterologous HEK293 cells. Wild-type IGSF1 migrated as a doublet of 140-150 kDa in protein blot analysis (Fig. 3a, lane 2) , reflecting the mature N-glycosylated and immature endoplasmic reticulum (ER)-resident forms of the CTD (Fig. 3a, lanes 3 and 4) 13 . In contrast, IGSF1 Ala713_Lys721del (family A; primer sequences are given in Supplementary Table 5 ) migrated predominantly as an immature form (Fig. 3a, lanes 5-7) . Similar migratory patterns were observed for IGSF1 Ser863Phe (family G; Fig. 3a; lanes 8-10) and the other two missense mutants (Cys947Arg (family H) and Ser770Asn (family K); Supplementary Fig. 3a, lanes  6-11) . The nonsense mutants in families B and I (p.Trp977*; Fig. 3a , lanes 11-13; p.Trp1173*, Supplementary Fig. 3a, lanes 17-19) and frameshift mutants in families C and D (p.Glu750Lysfs*28) and J (p.Glu1200Argfs*3) (Supplementary Fig. 3a, lanes 3-5 and 12-14) possessed immature sugars and were truncated relative to wild-type IGSF1. On the basis of their patterns of glycosylation, the identified IGSF1 mutants appeared to be retained in the ER.
To assess plasma membrane trafficking, we transfected HEK293 cells with constructs encoding wild-type and mutant IGSF1 and detected the expressed proteins by immunofluorescence with an antibody directed against the N terminus of the IGSF1 CTD. Membrane staining was observed in non-permeabilized cells transfected with the construct for wild-type IGSF1 (Fig. 3b) . A similar pattern was observed with IGSF1 Ala713_Lys721del and the three missense mutants (Fig. 3b and Supplementary Fig. 3b) ; however, cell surface biotinylation showed that mutant proteins reached the plasma membrane with poor efficiency and with distinct glycosylation patterns compared to wild-type protein (Fig. 3c) . Membrane signals were never detected in nonpermeabilized cells transfected with vectors expressing IGSF1 p.Trp977* (Fig. 3b) or the other truncated forms of the protein ( Supplementary  Fig. 3b) . We did not detect secreted proteins in the culture medium (data not shown). In contrast, we observed a strong intracellular staining pattern in permeabilized cells with all constructs (Fig. 3b  and Supplementary Fig. 3b ), confirming expression of the mutant proteins. Thus, the identified mutations block or substantially impair IGSF1 CTD plasma membrane trafficking.
To establish a causal link between loss of IGSF1 function and central hypothyroidism, we examined pituitary and thyroid function in Igsf1-deficient mice 17 (Supplementary Fig. 4) . mRNA levels for various pituitary hormone-encoding genes, including Tshb, did not differ between control and Igsf1-deficient mice ( Fig. 4a  and Supplementary Fig. 5a ). In contrast, both pituitary and serum TSH content was significantly reduced in adult Igsf1-deficient males (Fig. 4b,c) . Pituitary prolactin content was unaffected ( Supplementary  Fig. 5b ). Whereas circulating T3 concentrations were decreased in Igsf1-deficient males (Fig. 4d) , T4/FT4 concentrations were similar to those of controls in the majority of cases, and thyroid histology appeared normal (Supplementary Fig. 5c,d and data not shown). Reduced TSH synthesis and secretion (Fig. 4b,c) in spite of normal Tshb mRNA expression (Fig. 4a) in Igsf1-deficient mouse pituitaries suggested impaired TRH signaling. Consistent with this idea, pituitary Trhr mRNA levels were reduced, and hypothalamic Trh mRNA levels were increased, in Igsf1-deficient mice relative to controls (Fig. 4e,f) . Pituitary Gnrhr mRNA expression was not altered (data not shown). Finally, Igsf1-deficient males were heavier than their control littermates (29.9 ± 0.4 versus 28.2 ± 0.3 g at 12 weeks; P = 0.004). Thus, adult male Igsf1-deficient mice display several characteristics of central hypothyroidism.
IGSF1 was initially hypothesized to function as a pituitary inhibin coreceptor 15, 18, 19 , raising the possibility that macroorchidism in our cases might be linked to loss of inhibin activity and, therefore, enhanced FSH secretion. However, the putative role of IGSF1 as an inhibin coreceptor has been challenged by more recent binding and in vivo data 17, 19 . In our cases, serum FSH concentration was higher than that of LH but exceeded the reference range in only six cases ( Table 2) . Moreover, male Igsf1-deficient mice are fertile and have normal testicular size and FSH concentration (ref. 17 and Supplementary  Fig. 5a,e) . Therefore, at present, the mechanisms of testicular enlargement in our cases are unresolved.
In summary, our data delineate a new X-linked disorder in which loss-of-function mutations in IGSF1 cause central hypothyroidism, testicular enlargement and variable prolactin and GH deficiency. The identified human IGSF1 defects impair either expression or membrane trafficking of the IGSF1 CTD, consistent with a loss of protein function. 
MeTHodS
Methods and any associated references are available in the online version of the paper.
Accession codes. X-chromosome sequencing data were deposited at the LOVD3 database: http://databases.lovd.nl/shared/individuals/00000208 and http://databases.lovd.nl/shared/individuals/00000209.
Note: Supplementary information is available in the online version of the paper.
oNLINe MeTHodS DNA isolation. DNA was isolated from human whole blood using the Autopure LS system (Qiagen) and associated reagents, following the manufacturer's protocol. All participants provided written informed consent. The study was approved by the ethics committees of Leiden University Medical Center (Leiden, The Netherlands), Academic Medical Center (Amsterdam, The Netherlands), Anglia and Oxford MREC (Cambridge, UK), Great Ormond Street Hospital (London, UK), Erasmus University Medical Center (Rotterdam, The Netherlands) and the IRCCS Istituto Auxologico Italiano (Milan, Italy).
Exome enrichment and next-generation sequencing. X-chromosome exome enrichment was carried out using Agilent's SureSelect X chromosome oligonucleotide capture library according to the manufacturer's protocol, except that DNA was hybridized with half of the amount of suggested probe. Illumina Genome Analyzer IIx sequencing generated 51-bp paired-end reads. An overview of reads is shown in Supplementary Table 1 . Whole-exome sequencing was undertaken using the SureSelect Human All Exon 50Mb kit (Agilent Technologies). Sequencing was performed with the SOLiD 4 system (Applied Biosystems). Variants in dbSNP131 and the 1000 Genomes Project were filtered out for mutation screening. Whole-exome experiments, sequencing and preliminary analyses were undertaken at the Eastern Region Sequencing and Informatics Hub using the Genome Analysis Toolkit 31 .
Filtering strategy. In family A, variants shared by both boys were classified on the basis of their function; only exonic and splice-site variants were taken forward.
We then filtered out all variants present in the local, in-house exome sequencing database, dbSNP, 1000 Genomes Project, LOVD and HapMap Project with an allele frequency of >1% in populations of European ancestry, which yielded no promising results. We therefore examined the variant list generated by GMAP and SAMtools, as GMAP allows gap alignment and enables identification of larger insertions and deletions. The same filtering procedure was applied on these variants. For family B, we compared variants from the two brothers; only shared exonic and splice-site variants were taken forward to the filtering step. We filtered out all variants present in databases and the UK 10K genomes project and focused on previously unknown, shared homozygous or X-linked hemizygous variants, using public databases to identify plausible candidates.
Sanger sequence analysis. PCR was performed using Phire Hot Start II DNA polymerase (Finnzyme) following the manufacturer's protocol (primer sequences are listed in Supplementary Table 4) . Products were purified with the QIAquick PCR purification kit (Qiagen) and mixed with 10 pmol of forward or reverse primer and sequenced with the Applied Biosystems 96-capillary 3730xl system.
Microarrays.
We performed analysis on the cytogenetic whole-genome 2.7M array (Affymetrix) according to the manufacturer's protocol. In families C and D, this analysis identified the same haploblock of 23 Mb around the deletion (rs929590 to rs16979902), suggesting a common ancestral origin for these families, although no familial relationship is known for at least four generations.
Expression constructs. The epitope for the antibody to IGSF1 CTD encoded by the human Myc-IGSF1-HA construct (from P. Scheiffele) was modified (QuikChange, Stratagene) to match the mouse protein to facilitate detection with polyclonal antibody against IGSF1 CTD (P. Scheiffele). Mutations were introduced into the construct using QuikChange or Phusion (Thermo; to create the p.Ala713_Lys721del alteration) site-directed mutagenesis (primer sequences are listed in Supplementary Cell immunofluorescence. Under non-permeabilizing conditions, antiserum to IGSF1 CTD (1:500 dilution in serum-free DMEM) was applied to cells for 2 h at 37 °C in 5% CO 2 . Cells were transferred to room temperature, washed three times with serum-free DMEM and fixed with 4% paraformaldehyde (PFA). Cells were then washed three times with PBS and incubated in 5% BSA in PBS for 1 h. Secondary antibody (1:600 dilution in 5% BSA in PBS) was applied to cells for 1 h, and cells were washed three times with PBS and mounted using aqueous medium with DAPI. Under permeabilizing conditions, cells were fixed using 4% PFA, washed three times in PBS, incubated in 0.3% Triton X-100 in PBS (PBSX) and incubated in 5% BSA in PBSX for 1 h. Antiserum to IGSF1 CTD (1:500 dilution in 5% BSA in PBSX) was applied to cells for 2 h. Cells were washed three times with PBS. Secondary antibody (1:600 dilution in 5% BSA in PBSX) was applied for 1 h, and cells were washed three times with PBS and mounted under non-permeabilizing conditions.
Pituitary immunofluorescence.
The morning when a vaginal plug was detected was considered E0.5. Pregnant mice at E18.5 were sacrificed, and embryo heads were fixed overnight in 4% PFA at 4 °C and embedded in paraffin, with sections sliced with 5 µm thickness. Sections were treated as previously described 33 . Nonspecific binding was blocked using 5% BSA in PBS with 0.2% Tween-20 (PBST). Sections were incubated with primary antibodies (IGSF1 CTD, 1:500 dilution, and (from Santa Cruz Biotechnology) TSH (sc7815) and LH (sc7824), 1:400 dilution, and GH (sc10365) and prolactin (sc7805) 1:200 dilution, in blocking buffer) overnight at 4 °C. Sections were washed three times with PBST, incubated in biotin-conjugated horse secondary antibody to goat (1:150 dilution in blocking buffer) for 1 h, washed three times with PBST, incubated in Streptavidin-Texas Red (1:400 dilution in blocking buffer) and Alexa 488-conjugated goat secondary antibody to rabbit (1:600 dilution) for 1 h, washed three times with PBST and mounted.
Cell surface biotinylation. Transfected cells were washed three times with PBS and incubated in 1 ml of 0.5 mg/ml EZ-link-sulfo-NHS-LC-biotin (Thermo) for 30 min at 4 °C, washed three times with 100 mM glycine in PBS, harvested in lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) and lysed by sonication (9 W for 10 s). Lysates were centrifuged, supernatant was collected and immunoprecipitation was carried out using EZview anti-HA affinity gel (E6779, Sigma) according to the manufacturer's instructions. Lysates were then processed for protein blotting. After blocking, membrane was incubated in 2.5% milk in TBST with two drops each of A and B reagents from the Vectastain kit (Vector) for 30 min. Membrane was washed three times with 10-min washes in TBST, and signal was visualized using the Western Lightning Plus-ECL kit (PerkinElmer).
Animals. Igsf1-deficient mice have been described previously 17 . Tissue and blood collection was performed in accordance with institutional (McGill University) and federal guidelines.
In situ hybridization. In situ hybridization was performed as previously described 34 Hormone concentration measurements. At diagnosis, serum FT4, TSH, T3 and prolactin concentrations were determined in the laboratories of the participating departments. At follow-up, samples were investigated in the Endocrine Laboratory at Erasmus Medical Center (inhibin B and AMH) and the Laboratory of Endocrinology and Radiochemistry at the Academic Medical Center (other measurements). Plasma LH and FSH concentrations were analyzed on a Roche E170; intra-and interassay variations were <5%. Plasma T3 concentration was measured by in-house radioimmunoassay (RIA); intra-and interassay variations were 6.3% and 7.8%, respectively. FT4, FT3, TSH, prolactin and GH concentrations were analyzed by fluoroimmunoassay using the Delfia 1232 Fluorometer (PerkinElmer); intra-and interassay variations, respectively, were 5.1% and 6.8% (FT4), 7.7% and 11.3% (FT3), 4.2% and 5.7% (TSH), 3.4% and 5.3% (prolactin) and 3.8% and 6.2% (GH). Plasma testosterone concentration was analyzed by in-house RIA; intra-and interassay variations were 9.2% and 10.8%, respectively. Insulin was analyzed by chemiluminescence using Immulite 2000 (Siemens); intra-and interassay variations were 3.7% and 5.1%, respectively. Serum inhibin B and AMH concentrations were estimated using enzyme immunometric methods (Beckman Coulter). For AMH concentration, the Gen II assay was used; intra-and interassay variations were published previously 35, 36 .
Mouse pituitary TSH and PRL content measurement was previously described 37 and used reagents supplied by A.L. Parlow (National Hormone and Peptide Program). In Chicago, serum total T4 and T3 levels were measured by coated-tube RIA (Siemens Medical Solutions Diagnostics) adapted for mouse. TSH concentration was measured as previously described 38 . Free T4 levels were estimated from the ratio of total T4 to resin T4 uptake and expressed as the free T4 index (FT4I) as described 39 .
Quantitative PCR. Mouse RNA was extracted from whole pituitaries and 3-mm hypothalamic blocks according to the following coordinates 40 : anteroposterior-interaural 3.94 to 0.94 mm, dorsoventral-interaural 2.5 mm and below, and 1.44 mm lateral. RNA (2 µg) was extracted and reverse transcribed as previously described 32 . Quantitative PCR (qPCR) was performed using Platinum SYBR Green qPCR SuperMix UDG (Invitrogen) and 0.4 pmol of each primer (Supplementary Table 6 ) on a Corbett Rotor-Gene 6200 HRM, using the manufacturer's protocol. Transcript levels were normalized to those of Rpl19 (encoding ribosomal protein L19) and analyzed using the 2 −∆∆CT method 41, 42 . Figure 4 and all supplementary figures, statistical significance was defined as P < 0.05 and was determined by two-tailed Student's t test.
Statistics. In

